Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life
- PMID: 15741257
- DOI: 10.1210/jc.2004-2297
Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life
Abstract
Active acromegaly is associated with significant comorbidity and reduced quality of life. However, the prevalence of comorbidity after long-term remission is not established. Therefore, we assessed the presence of comorbidity in 118 patients in long-term remission after surgery, radiotherapy, and/or somatostatin analog treatment according to strict biochemical criteria of serum GH and IGF-I concentrations and evaluated the impact of comorbidity on quality of life. The mean duration of remission was 12.0 +/- 7.4 yr, and mean actual IGF-I sd scores were 0.6 +/- 1.7. Self-reported joint problems occurred in 77% of patients, hypertension in 37%, a history of myocardial infarction in 9%, and diabetes mellitus in 11%. The presence of joint problems was not related to GH and IGF-I levels, active disease duration, or age. Joint complaints had significant negative impact on quality of life. Patients with a history of myocardial infarction had reduced scores for general health, depression, and fatigue, and diabetes mellitus was associated with reduced scores for anxiety and sleep. In conclusion, acromegalic patients had a high prevalence of joint-related comorbidity and hypertension despite long-term control of GH excess. Especially, joint complaints contributed to a reduced perceived quality of life in these patients.
Similar articles
-
Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.J Clin Endocrinol Metab. 2004 Nov;89(11):5369-76. doi: 10.1210/jc.2004-0669. J Clin Endocrinol Metab. 2004. PMID: 15531483
-
Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.Growth Horm IGF Res. 2010 Jun;20(3):226-33. doi: 10.1016/j.ghir.2010.02.003. Epub 2010 Mar 2. Growth Horm IGF Res. 2010. PMID: 20194043
-
Quality of life in treated patients with acromegaly.J Clin Endocrinol Metab. 2006 Oct;91(10):3891-6. doi: 10.1210/jc.2006-0676. Epub 2006 Jul 18. J Clin Endocrinol Metab. 2006. PMID: 16849407
-
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Acta Diabetol. 2009. PMID: 19322513 Review.
-
Arthropathy in acromegaly.Rheum Dis Clin North Am. 2010 Nov;36(4):713-20. doi: 10.1016/j.rdc.2010.09.004. Rheum Dis Clin North Am. 2010. PMID: 21092848 Review.
Cited by
-
Pituitary tumors: coping with ‘cured’ pituitary tumors.Nat Rev Endocrinol. 2011 May;7(5):251-2. doi: 10.1038/nrendo.2011.39. Nat Rev Endocrinol. 2011. PMID: 21364514 No abstract available.
-
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.J Endocrinol Invest. 2008 Sep;31(9):820-38. doi: 10.1007/BF03349263. J Endocrinol Invest. 2008. PMID: 18997495 Review.
-
Quality of Life in Patients with Acromegaly - A Romanian Single Center Cross-Sectional Study.Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):42-50. doi: 10.4183/aeb.2021.42. Acta Endocrinol (Buchar). 2021. PMID: 34539909 Free PMC article.
-
Improving Quality of Life in Patients with Pituitary Tumours.Eur Endocrinol. 2013 Mar;9(1):32-36. doi: 10.17925/EE.2013.09.01.32. Epub 2013 Mar 15. Eur Endocrinol. 2013. PMID: 30349608 Free PMC article. Review.
-
Higher Income and Integration into the Workforce Are the Main Factors Associated with Quality of Life in Acromegalic Patients in Northeastern Brazil.Int J Endocrinol. 2018 Feb 27;2018:6135080. doi: 10.1155/2018/6135080. eCollection 2018. Int J Endocrinol. 2018. PMID: 29681935 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical